These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 7912486)

  • 21. Derivatives of 1,2-diazetidine-1,2-di-N-oxides--a new class of soluble guanylate cyclase activators with vasodilatory properties.
    Severina IS; Ryaposova IK; Volodarsky LB; Mozhuchin DC; Tichonov AYa ; Schwartz GYa ; Granik VG; Grigoryev DA; Grigoryev NB
    Biochem Mol Biol Int; 1993 Jun; 30(2):357-66. PubMed ID: 8103389
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular basis of the synergistic inhibition of platelet function by nitrovasodilators and activators of adenylate cyclase: inhibition of cyclic AMP breakdown by cyclic GMP.
    Maurice DH; Haslam RJ
    Mol Pharmacol; 1990 May; 37(5):671-81. PubMed ID: 2160060
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sex and age differences in soluble guanylate cyclase activity in human platelets.
    Michimata T; Imamura M; Mizuma H; Murakami M; Iriuchijima T
    Life Sci; 1996; 58(5):415-9. PubMed ID: 8594306
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evidence that additional mechanisms to cyclic GMP mediate the decrease in intracellular calcium and relaxation of rabbit aortic smooth muscle to nitric oxide.
    Weisbrod RM; Griswold MC; Yaghoubi M; Komalavilas P; Lincoln TM; Cohen RA
    Br J Pharmacol; 1998 Dec; 125(8):1695-707. PubMed ID: 9886761
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Regulation of platelet guanylyl cyclase by collagen: evidence that Glycoprotein VI mediates platelet nitric oxide synthesis in response to collagen.
    Riba R; Sharifi M; Farndale RW; Naseem KM
    Thromb Haemost; 2005 Aug; 94(2):395-403. PubMed ID: 16113831
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cellular signaling with nitric oxide and cyclic GMP.
    Murad F
    Braz J Med Biol Res; 1999 Nov; 32(11):1317-27. PubMed ID: 10559832
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Soluble guanylyl cyclase activation with HMR1766 attenuates platelet activation in diabetic rats.
    Schäfer A; Flierl U; Kobsar A; Eigenthaler M; Ertl G; Bauersachs J
    Arterioscler Thromb Vasc Biol; 2006 Dec; 26(12):2813-8. PubMed ID: 17023677
    [TBL] [Abstract][Full Text] [Related]  

  • 28. eNOS, iNOS or no NOS, that is the question!
    Naseem KM
    J Thromb Haemost; 2008 Aug; 6(8):1373-5. PubMed ID: 18503634
    [No Abstract]   [Full Text] [Related]  

  • 29. Increase in activating ability of human platelet guanylate cyclase during aggregation.
    Severina IS; Belushkina NN
    Biochem Int; 1992 Dec; 28(4):621-31. PubMed ID: 1362351
    [TBL] [Abstract][Full Text] [Related]  

  • 30. YC-1 inhibited human platelet aggregation through NO-independent activation of soluble guanylate cyclase.
    Wu CC; Ko FN; Kuo SC; Lee FY; Teng CM
    Br J Pharmacol; 1995 Oct; 116(3):1973-8. PubMed ID: 8640334
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [The soluble form of guanylate cyclase in the molecular mechanism of the physiological effects of nitric oxide and in regulating platelet aggregation].
    Severina IS
    Biull Eksp Biol Med; 1995 Mar; 119(3):230-5. PubMed ID: 7795182
    [No Abstract]   [Full Text] [Related]  

  • 32. Differential effects of soluble and particulate guanylyl cyclase on Ca(2+) sensitivity in airway smooth muscle.
    Rho EH; Perkins WJ; Lorenz RR; Warner DO; Jones KA
    J Appl Physiol (1985); 2002 Jan; 92(1):257-63. PubMed ID: 11744668
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Smooth muscle-specific deletion of nitric oxide-sensitive guanylyl cyclase is sufficient to induce hypertension in mice.
    Groneberg D; König P; Wirth A; Offermanns S; Koesling D; Friebe A
    Circulation; 2010 Jan; 121(3):401-9. PubMed ID: 20065162
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [The role of guanyl cyclase in the regulation of aggregation of human thrombocytes].
    Chirkov IuIu; Belushkina NN; Tyshchuk IA; Severina IS
    Vestn Akad Med Nauk SSSR; 1991; (10):51-4. PubMed ID: 1686950
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Analysis of nitric oxide-sensitive guanylyl cyclase in human platelets before and after aggregation.
    Kempfert J; Behrends S
    Platelets; 2003; 14(7-8):429-35. PubMed ID: 14713512
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Praliciguat and Soluble Guanylate Cyclase Stimulators for Peripheral Artery Disease.
    Kosmac K; Ismaeel A; Kim-Shapiro DB; McDermott MM
    Circ Res; 2023 Jan; 132(1):49-51. PubMed ID: 36603062
    [No Abstract]   [Full Text] [Related]  

  • 37. Dehydroepiandrosterone upregulates soluble guanylate cyclase and inhibits hypoxic pulmonary hypertension.
    Oka M; Karoor V; Homma N; Nagaoka T; Sakao E; Golembeski SM; Limbird J; Imamura M; Gebb SA; Fagan KA; McMurtry IF
    Cardiovasc Res; 2007 Jun; 74(3):377-87. PubMed ID: 17346686
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Activation of guanylate cyclase and the regulatory role of cyclic 3',5'-guanosine monophosphate.
    Severina IS
    Biochem Int; 1988 Aug; 17(2):265-78. PubMed ID: 2903739
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Guanylate cyclase from human blood platelets].
    Chirkov IuIu; Tyshchuk IA; Belushkina NN; Severina IS
    Biokhimiia; 1987 Jun; 52(6):956-63. PubMed ID: 2889477
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nitric oxide signaling in platelets.
    Low SY; Bruckdorfer KR
    Methods Mol Biol; 2004; 273():313-34. PubMed ID: 15308809
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.